Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

Creative Commons License

Maen A., Gok Yavuz B., Mohamed Y. I., Esmail A., Lu J., Mohamed A., ...More

Frontiers in Pharmacology, vol.15, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15
  • Publication Date: 2024
  • Doi Number: 10.3389/fphar.2024.1291212
  • Journal Name: Frontiers in Pharmacology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Veterinary Science Database, Directory of Open Access Journals
  • Keywords: Coronavirus, COVID-19, COVID-19 and anti-viral agents, fatty acids, Thymoquinone TQ, TQ formula
  • Istanbul Medipol University Affiliated: Yes


Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.